Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Brain Neoplasms 640Glioblastoma 573Glioma 407Neuroblastoma 174Neoplasms 125Astrocytoma 107Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Carcinoma, Non-Small-Cell Lung 78Melanoma 76Lung Neoplasms 70Sarcoma 65Ependymoma 64Neurofibromatosis 1 62Recurrence 50Neoplasm Metastasis 48Oligodendroglioma 47Meningeal Carcinomatosis 47Osteosarcoma 46Diffuse Intrinsic Pontine Glioma 45Rhabdomyosarcoma 44Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Pancreatic Neoplasms 39Sarcoma, Ewing 38Colorectal Neoplasms 33

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × CNS × 1 year × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡